DGAP-News

Novavax Reports Second-Quarter 2014 Financial Results - Seite 3

expenses, partially offset by lower professional fees.

As of June 30, 2014, the company had $208.8 million in cash and cash
equivalents and investments compared to $133.1 million as of December 31, 2013.
In June 2014, the company raised net proceeds of approximately $108 million
through the sale of its common stock. Net cash used in operating activities for
the six months of 2014 was $31.4 million compared to $18.2 million for the same
period in 2013. The factors contributing to the increase in cash usage are as
described above.

Conference Call
Date: August 6, 2014
Time: 4:30 PM US eastern time
Dial-in number: 1 [phone] (domestic) or 1 [phone]
(international)
Via Web: www.novavax.com

Conference call
Replay:
Dates: Starting at 6:31 PM on August 6, 2014 until midnight
October 6, 2014
Dial-in number: 1 [phone] (domestic) or 1 [phone]
(international)
Passcode: 82216889
Via-Web: www.novavax.com, 'Investor Info'/'Events'

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating novel vaccines and vaccine adjuvants to address a broad range of
infectious diseases worldwide. Using innovative proprietary recombinant
nanoparticle vaccine technology, the company produces vaccine candidates to
efficiently and effectively respond to both known and newly emergent diseases.
Additional information about Novavax is available on the company's website,
novavax.com.

Novavax Inc., Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development
of its vaccine and adjuvant products are forward-looking statements. Novavax
cautions that these forward looking statements are subject to numerous risks
and uncertainties, which could cause actual results to differ materially from
those expressed or implied by such statements. These risks and uncertainties